Alnylam lung drug fails mid-stage trial






Alnylam lung drug fails mid-stage trial



(Reuters) - Alnylam Pharmaceuticals Inc's experimental drug to treat a type of respiratory infection in lung transplant patients missed the main goal of a mid-stage trial. The drug, codenamed ALN-RSV01, is being developed to treat respiratory syncytial virus (RSV) infection that causes respiratory illness in young children. "We have questioned the investment in this trial since before it even began and removed all value for the RSV program from our target in January 2011," analyst Edward Tenthoff said. ...






Popular posts from this blog

One dead, more than dozen hurt as storm rips through baseball party tent

Which Wedding Style Is The Best Fit For A Couple?

Mysterious African 'Fairy Circles' Stump Scientists